Drug Type Small molecule drug |
Synonyms 依鲁奥克, FL-006, WX 0593 + [2] |
Target |
Action inhibitors |
Mechanism ALK inhibitors(Anaplastic lymphoma kinase inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (27 Jun 2023), |
Regulation- |
Molecular FormulaC29H38ClN6O2P |
InChIKeyZPCCNHQDFZCULN-UHFFFAOYSA-N |
CAS Registry1854943-32-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
ALK positive Non-Small Cell Lung Cancer | China | 27 Jun 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | - | 30 Apr 2022 |
Locally Advanced Unresectable Carcinoma | Phase 2 | China | - | 30 Apr 2022 |
Reactive oxygen species 1 positive non-small cell lung cancer | Phase 2 | China | 07 Mar 2019 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 14 Sep 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 14 Sep 2017 | |
ALK Positive Solid Tumors | Phase 1 | China | 14 Sep 2017 | |
ROS1 positive Solid Tumors | Phase 1 | China | 14 Sep 2017 |
Not Applicable | ALK positive Lung Cancer ALK-positive | 11 | Iruplinalkib 180 mg | wksvxcmhvb(moqgsobrwi) = nugkiqinkl uazovmkynv (rzdxdkolvj ) View more | Positive | 30 May 2025 | |
Phase 2 | Reactive oxygen species 1 positive non-small cell lung cancer Neoadjuvant | Adjuvant | 10 | Iruplinalkib 180 mg/day | npkyrsdmtn(sgohkcpaoc) = pfzuneahxt rahfssbyhu (hdjcaharcg ) View more | Positive | 30 May 2025 | |
Phase 1 | Unresectable Lung Non-Small Cell Carcinoma ALK+ | ROS1+ | 8 | CRT + Iruplinalkib | mjvfbmfouq(ivpvatjzsr) = wxgkzaapwz vyvuvfjjau (bkzugyjnym, 59% - 100%) View more | Positive | 01 Oct 2024 | |
Phase 3 | 292 | rucmfbputg(tilhzatxsv) = ukdnlvhmst pwfqwccumf (yqbbicedau ) View more | Positive | 14 Sep 2024 | |||
rucmfbputg(tilhzatxsv) = gjalgpzcbs pwfqwccumf (yqbbicedau ) View more | |||||||
Phase 2 | ALK positive Non-Small Cell Lung Cancer ALK-Positive | 146 | Iruplinalkib 60 mg once daily | gpwhlmtxjp(rhqcsqltjv) = evsdxrilyi rqufueoltf (redqciewzq, 11.73 - 19.98) View more | Positive | 08 Sep 2024 | |
Iruplinalkib 180 mg once daily | elzkfohjze(ajicunpoft) = ziqeashmto upcqvvgqaj (pdnchsqyoi, 48.0 - 78.4) View more | ||||||
Phase 3 | ALK positive Non-Small Cell Lung Cancer ALK positive | 292 | frmaxximue(vvgrscnynf) = eqocybwypm jcfolixyoh (seuzucxspm, 26.3 - NE) View more | Positive | 01 Jun 2024 | ||
frmaxximue(vvgrscnynf) = mvrinixfkh jcfolixyoh (seuzucxspm, 11.1 - 16.5) View more | |||||||
Phase 2 | ALK positive Non-Small Cell Lung Cancer | Reactive oxygen species 1 positive non-small cell lung cancer ALK Positive | ROS1 Positive | 8 | acikjjyfrh(fsifdhifwp) = yrdwisynzq rwapptklzc (wgmipsvcwe ) View more | Positive | 22 Mar 2024 | ||
Phase 1 | ALK positive Non-Small Cell Lung Cancer ALK-positive | ROS1-positive | 153 | eohmxathsd(nmoliydpgm) = xdkfuarusm gannzodlfx (xxbtndhwcp ) View more | Positive | 02 Dec 2023 | ||
NCT04632758 (WCLC2023) Manual | Phase 3 | ALK positive Non-Small Cell Lung Cancer ALK Positive | 292 | vzbhchrtff(eqlxbilknc) = nauteqrkma montiizwne (oveadlfnnl, 26.25 - NE) View more | Positive | 10 Sep 2023 | |
vzbhchrtff(eqlxbilknc) = kpqdotarix montiizwne (oveadlfnnl, 11.07 - 16.49) View more | |||||||
Phase 2 | 146 | Iruplinalkib 180 mg | lvnzhzdvko(wnskowidzu) = nscdskptry pnihpnsphx (czkurjrohv, 61.7 - 77.2) View more | - | 24 Feb 2023 |